Miyotonik Distrofi

Miyotonik distrofi (MD) seyrek görülen, otozomal dominant kalıtım ve multisistemik tutulumla seyreden ilerleyici bir kas hastalığıdır. MD hastalarında kas tutulumunun ilerleyici olması hastaların günlük yaşam aktivitelerinde bağımlılık gibi olumsuz etkiler doğurmaktadır. Bu yüzden bu hastaların medikal tedavi ve rehabilitasyonu oldukça önemlidir. Bu olgu serisinde MD tanısı olan 3 olgu gözden geçirildi. Kliniğimizde yatarak tedavi gören 3 MD hastasına 4 hafta geleneksel egzersiz programı ve fonksiyonel elektrik stimulasyonu (FES) tedavisi verildi, hastalar tedavi öncesi ve sonrası değerlendirildi. Hastalara uygulanan rehabilitasyon programı; eklem hareket açıklığı egzersizleri, solunum egzersizleri, ayakta durma eğitimi, yürüme eğitimi, denge koordinasyon egzersizleri, ayak bileği ve el bileği dorsifleksörlerine FES uygulamasını içeriyordu. Hastaların tedavi öncesi ve tedavi sonrası değerlendirme ölçekleriyle dökümente ettiğimiz klinik bulgularında olumlu değişiklikler bulundu.

Myotonic Dystrophy

Myotonic dystrophy (MD) is a rare, progressive muscle disease, characterizedby autosomal dominant heredity and multisystem involvement. The muscleinvolvement’s being progressive in MD patients leads to negative effects suchas dependency of the patients in their daily activities. For this reason, medicaltreatment and rehabilitation of these patients are very important. We considered3 patients with MD diagnosis in this series of cases. We made pre-treatment andpost-treatment evaluations of 3 patients who were hospitalized in our clinic bygiving them a 4 week conventional exercise program and functional electricalstimulation (FES) treatment. The rehabilitation program we applied to the patientscontained joint’s range of motion exercises, breathing exercises, standing training,gait training, balance coordination exercises, and FES application to ankle andwrist dorsiflexors. We achieved positive changes in the clinical findings that wedocumented with pre-treatment and post-treatment assessment values.

PDF

___

Suominen T, Bachinski LL, Auvinen S, Hackman P, Baggerly KA, Angelini C, et al. Population frequency of myotonic dystrophy: higher than expected frequency of myotonic dystrophy type 2 (DM2) mutation in Finland. Eur J Hum Genet 2011; 19: 776-82.
Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3’ end of a transcript encoding a protein kinase family member. Cell 1992; 69: 385.
Harley HG, Rundle SA, Reardon W, Myring J, Crow S, Brook JD, et al. Unstable DNA sequence in myotonic dystrophy. Lancet 1992; 339: 1125-8.
Brandom BW, Veyckemans F. Neuromuscular diseases in children: a practical approach. Paediatr Anaesth 2013; 23: 765-9.
Mateos-Aierdi AJ, Goicoechea M, Aiastui A, Fernández-Torrón R, Garcia-Puga M, Matheu A, et al. Muscle wasting in myotonic dystrophies: a model of premature aging. Front Aging Neurosci 2015; 7: 125.
Ho G, Cardamone M, Farrar M. Congenital and childhood myotonic dystrophy: Current aspects of disease and future directions. World J Clin Pediatr 2015; 4: 66-80.
Trip J, Drost G, van Engelen BG, Faber CG. Drug treatment for myotonia. Cochrane Database Syst Rev 2006; CD004762.
van der Kooi EL, Lindeman E, Riphagen I. Strength training and aerobic exercise training for muscle disease. Cochrane Database Syst Rev 2005; CD003907.
Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45.
Holden MK, Gill KM, Magliozzi MR, Nathan J, Piehl-Baker L. Clinical gait assessment in the neurologically impaired. Reliability and meaningfulness. Phys Ther 1984; 64: 35-40.
EDITORIAL : The accuracy of the manual muscle test. Arch Phys Med Rehabil 1954; 35: 515-7.
Allison L, Fuller K. Balance and vestibular disorders. In: Neurological Rehabilitation Umphred D (eds), Aharcourt Health Sciences Company, New York 2000; 116: 616-60.
Palisano RJ, Hanna SE, Rosenbaum PL, Russell DJ, Walter SD, Wood EP, et al. Validation of a model of gross motor function for children with cerebral palsy. Phys Ther 2000; 80: 974-85.
Turner C, Hilton-Jones D. Myotonic dystrophy: diagnosis, management and new therapies. Curr Opin Neurol 2014; 27: 599-606.
Aldehag A, Jonsson H, Lindblad J, Kottorp A, Ansved T, Kierkegaard M. Effects of hand-training in persons with myotonic dystrophy type 1--a randomised controlled cross-over pilot study. Disabil Rehabil 2013; 35: 1798-807.
Voet NB, van der Kooi EL, Riphagen II, Lindeman E, van Engelen BG, Geurts AC. Strength training and aerobic exercise training for muscle disease. Cochrane Database Syst Rev 2013; CD003907.
Kierkegaard M, Harms-Ringdahl K, Edström L, Widén Holmqvist L, Tollbäck A. Feasibility and effects of a physical exercise programme in adults with myotonic dystrophy type 1: a randomized controlled pilot study. J Rehabil Med 2011; 43: 695- 702.
Cudia P, Weis L, Baba A, Kiper P, Marcante A, Rossi S, et al. Effects of Functional Electrical Stimulation Lower Extremity Training in Myotonic Dystrophy Type I: A Pilot Controlled Study. Am J Phys Med Rehabil 2016; 95: 809-17.
Chisari C, Bertolucci F, Dalise S, Rossi B. Chronic muscle stimulation improves muscle function and reverts the abnormal surface EMG pattern in myotonic dystrophy: a pilot study. J Neuroeng Rehabil 2013; 10: 94.